drugset

drugset / Trial / NCT02783625

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

NCT02783625 ↗

Phase 1 Completed 114 enrolled Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute · collab Stanford University · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of a study drug called duvelisib.

Timeline

Start: 2016-05-23
Primary completion: 2026-04-21
Completion: 2026-04-21

Publications

Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. Nat Med. 2024 Sep;30(9):2517-2527. doi: 10.1038/s41591-024-03076-6. Epub 2024 Jun 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	—	Subcutaneous
Subject	Duvelisib	Small molecule	25 mg	Oral
Subject	Duvelisib	Small molecule	75 mg	Oral
Subject	Romidepsin	Peptide	—	Intravenous

Indications